7649:TSESugi Holdings Co., Ltd. Analysis

Sugi Holdings is trading at ¥3,398, just above its near‑term support of ¥3,360 and well below its 20‑day SMA of ¥3,528, indicating a modest upside cushion. The 14‑day RSI sits at 38, suggesting the stock is approaching oversold territory, while the MACD remains bearish with the histogram below zero. Volatility is elevated at roughly 27% over the past 30 days, but the beta is slightly negative (-0.08), implying limited correlation with broader market moves. Valuation appears attractive: the trailing P/E of 14.9 is far beneath the industry average of 26.2, and the price‑to‑book of 2.19 aligns with a fair multiple for a healthcare retailer. Dividend yield stands at 1.03% with a modest payout ratio of 15%, supported by strong cash balances and a manageable debt‑to‑equity of 34%. The consensus analyst outlook is “Buy” with a target median price of ¥3,800, representing a 14% upside from current levels.
Fundamentally, revenue grew 13.2% YoY, though margins remain thin (gross 31.6%, operating 4.2%). The company benefits from Japan’s aging demographics and expanding health‑care services, providing a stable earnings base for the dividend. While regulatory scrutiny in the pharmaceutical retail space is moderate, the low geographic concentration and limited currency exposure keep those risks contained. Overall, the combination of undervalued pricing, solid cash generation, and a favorable market sentiment (Fear‑Greed Index at 72, “Greed”) supports a positive investment case across horizons.